Literature DB >> 17912159

Evolution of a prolactin-secreting pituitary microadenoma into a fatal carcinoma: a case report.

E Guastamacchia1, V Triggiani, E Tafaro, A De Tommasi, C De Tommasi, S Luzzi, C Sabbà, F Resta, M R Terreni, M Losa.   

Abstract

Pituitary carcinomas are very rare tumors, nearly always presenting as widely invasive masses, although the hallmark of these lesions is the finding of distant metastases. One third of reported cases are prolactin (PRL)-secreting tumors. We report the case of a fatal pituitary carcinoma evolving within 4 years from a PRL-secreting microadenoma. A 22-year-old woman presented because of galactorrhea. Evaluation of the patient disclosed slight hyperprolactinemia and magnetic resonance imaging (MRI) showed a 7-mm intrapituitary lesion, which responded to treatment with cabergoline. About 4 years after the first evaluation she developed sudden headache, ptosis, and diplopia in the right eye. MRI disclosed the growth of a large pituitary mass, invading the right cavernous sinus. Despite two trans-sphenoidal surgical procedures followed by gamma-knife radiosurgery, the patient showed rapid local progression of the tumor and the occurrence of new lung lesions, probably of metastatic nature. The patient died 7 months after the development of her first neurological symptoms because of tumor apoplexy and subsequent subarachnoid hemorrhage. This case represents the first documented rapid evolution from a microprolactinoma initially responding to dopamine agonists to a fatal pituitary carcinoma.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17912159

Source DB:  PubMed          Journal:  Minerva Endocrinol        ISSN: 0391-1977            Impact factor:   2.184


  7 in total

1.  Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide.

Authors:  Genya Aharon-Hananel; Ruth Percik; Muhamad Badarna; Inbal Uri; Amit Tirosh
Journal:  Endocrine       Date:  2019-07-02       Impact factor: 3.633

2.  An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.

Authors:  Omalkhaire M Alshaikh; Sylvia L Asa; Ozgur Mete; Shereen Ezzat
Journal:  Endocr Pathol       Date:  2019-06       Impact factor: 3.943

3.  Atypical pituitary adenoma with malignant features.

Authors:  Adam N Mamelak; John D Carmichael; Patricia Park; Sergei Bannykh; Xuemo Fan; H Vivien Bonert
Journal:  Pituitary       Date:  2011-03       Impact factor: 4.107

Review 4.  The cell-based approach in neurosurgery: ongoing trends and future perspectives.

Authors:  Sabino Luzzi; Alberto Maria Crovace; Mattia Del Maestro; Alice Giotta Lucifero; Samer K Elbabaa; Benedetta Cinque; Paola Palumbo; Francesca Lombardi; Annamaria Cimini; Maria Grazia Cifone; Antonio Crovace; Renato Galzio
Journal:  Heliyon       Date:  2019-11-26

Review 5.  Evolution of a refractory prolactin-secreting pituitary adenoma into a pituitary carcinoma: report of a challenging case and literature review.

Authors:  Congxin Dai; Bowen Sun; Shusen Guan; Wei Wang; Honggang Liu; Yong Li; Jialiang Zhang; Jun Kang
Journal:  BMC Endocr Disord       Date:  2021-10-29       Impact factor: 2.763

6.  Orbital metastasis of pituitary growth hormone secreting carcinoma causing lateral gaze palsy.

Authors:  Rohan R Lall; Stephen F Shafizadeh; Kyung-Hwa Lee; Qinwen Mao; Minesh Mehta; Jeffrey Raizer; Bernard R Bendok; James P Chandler
Journal:  Surg Neurol Int       Date:  2013-04-18

7.  ACTH-producing carcinoma of the pituitary with refractory Cushing's Disease and hepatic metastases: a case report and review of the literature.

Authors:  Scott N Pinchot; Rebecca Sippel; Herbert Chen
Journal:  World J Surg Oncol       Date:  2009-04-08       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.